AbCellera Biologics Inc. (ABCL) Stock Price & How to Invest

AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Since 2023 it has deliberately scaled back partnership volume to redirect resources into its own internal pipeline, marking a shift from a services-and-royalties model toward being a clinical-stage drug developer that captures more of the upside if its molecules succeed.

The investment picture is a classic pre-profit biotech setup: modest and lumpy platform revenue, sizeable R&D-driven net losses, and a large balance sheet (roughly $531M in cash and marketable securities plus additional non-dilutive government funding) meant to fund the pipeline for years. The story now rides on two lead assets, ABCL-635 for menopausal vasomotor symptoms and ABCL-575 for atopic dermatitis, both with top-line data expected in 2026. That makes the stock highly catalyst-sensitive: strong readouts could re-rate it, while disappointments would leave a company valued well above its trailing fundamentals.

AbCellera is unprofitable and burning cash, posting a net loss of roughly $43M in Q1 2026 against only about $8M of quarterly revenue, so the market value rests on future clinical success rather than current earnings. Its stock is highly binary: a miss on the ABCL-635 or ABCL-575 readouts could sharply reset the valuation. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large) and is lumpy and partner-dependent. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses could eventually require dilutive financing.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AbCellera Biologics Inc.'s investor relations page or your broker.

• Market cap: ~$2.4B
• Share price: ~$7.70
• Revenue (Q1 2026): ~$8.3M (up from ~$4.2M yr-ago)
• Net loss (Q1 2026): ~$43M
• Cash & marketable securities: ~$531M
• Total available liquidity: ~$655M

AbCellera has no P/E because it is unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality: a large portion of the roughly $2.4B market value is backed by its cash and liquidity, with the remainder pricing the pipeline. Revenue is small and lumpy relative to the market cap, which is normal for a clinical-stage biotech but means the shares trade on catalysts, not fundamentals. Analyst views vary; for example Benchmark upgraded the stock to Buy with an $11 target, reflecting how much depends on the 2026 readouts.

There are three common ways to get ABCL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ABCL sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ABCL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

AbCellera is a well-funded, pre-profit antibody developer whose value hinges on 2026 pipeline data, so it fits an investor comfortable with high-variance, catalyst-driven biotech risk.

Whether ABCL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ABCL a buy?, and where the stock could go from here in the ABCL stock forecast.

For income investors, whether ABCL pays a dividend and how the payout looks is covered in does ABCL pay a dividend?